Drug Type Small molecule-drug conjugates |
Synonyms ELU 001, ELU-001 |
Target |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Elucida Oncology, Inc.Startup |
Active Organization Elucida Oncology, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
endometrial clear cell carcinoma | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Endometrioid Carcinoma | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Fallopian Tube Carcinoma | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Krukenberg Tumor | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Ovarian adenocarcinoma | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Ovarian Serous Adenocarcinoma | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Peritoneal Neoplasms | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Recurrent Endometrial Cancer | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Recurrent ovarian cancer | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
Uterine Carcinosarcoma | Phase 2 | US | Elucida Oncology, Inc.Startup | 13 Sep 2021 |
NCT05001282 (ESMO2023) Manual | Phase 1/2 | Solid tumor FRα overexpression | 40 | lywlcxbssv(lhgduojkjc) = fvgzmjttph mlfjfptdna (ympptiadtd ) View more | Positive | 23 Oct 2023 |